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 Nuclear medicine at the Hammersmith Hospital was established as a separate unit by 
Peter Lavender in the early seventies. It was called the Radioisotope Unit to distin-
guish it from the pre-existing Department of Medical Physics, headed by Harold 
Glass who was one of the early pioneers in medical radioisotope scanners [ 1 ]. As well 
as providing a clinical service, the unit, which only comprised two rooms, was active 
in clinical research complemented by the extensive academic activities of the MRC 
Cyclotron Unit. Two good examples of these activities that launched nuclear medicine 
at Hammersmith are fi rstly the development by Clark, Watson Fazio and Jones of 
Kr-81m for ventilation and perfusion studies [ 2 ], and secondly, cell labelling. 
 Kr-81m is a 13 s half-life radionuclide that is the metastable daughter of Rb-81, 
which has a half-life of 4.7 h. To obtain Kr-81m gas, oxygen is passed through the 
generator. There was an enthusiastic response to the generator across the UK, and, 
at one point, Kr-81m/Tc-99m ventilation/perfusion imaging was the second most 
frequently performed imaging procedure in the UK after bone scanning. Whilst 
Kr-81m remains the optimal ventilation agent for lung scanning, it is not so widely 
appreciated that Lavender and his colleagues also administered Kr-81 in solution to 
measure tissue perfusion. To obtain Kr-81m in solution, isotonic glucose is passed 
through the generator. For example, Harvey-Turner and Selwyn infused Kr-81m 
into the aortic root of dogs and continuously imaged regional changes in myocardial 
perfusion in response to transient coronary artery occlusion [ 3 ]. The distribution of 
pulmonary blood fl ow in humans was also imaged by continuous intravenous 
 infusion [ 4 ]. Kr-81m was given both by inhalation and infusion to study ventilation- 
perfusion ratios and regional lung function in adults [ 4 ,  5 ] and children [ 6 ], When 
combined with the longer half-life Kr-85 (a lung gas volume marker), regional lung 
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function per unit volume could be assessed. Lavender used Kr-81m/Tc-99m SPECT 
in the early eighties to study pulmonary physiology [ 7 ] but did not feel that it offered 
any great advantage over planar imaging for diagnosing pulmonary thrombo- 
embolic disease. 
 The second example of innovative collaboration between Hammersmith nuclear 
medicine and MRC Cyclotron Unit was the development of cell labelling by Thakur 
and McAfee. John McAfee came to the Hammersmith for a 6 month sabbatical with 
the specifi c aim of working with Matthew Thakur to develop cell labelling for clini-
cal imaging. Cr-51 had already been developed for cell labelling but is not suitable 
for gamma camera imaging, only surface counting. Testing several combinations of 
lipophilic chelating agents and radiometals, Thakur and McAfee came up with 
In-111 and hydroxyquinoline (oxine). The fi rst full paper on leucocyte scanning for 
sepsis, based on 15 patients, was published in 1977 ([ 8 ]; Fig.  12.1 ).
 Fig. 12.1  A patient with multiple sites of sepsis imaged with In-111-labelled leucocytes 




 There was great hope for performing labelled lymphocyte studies too, until it 
was soon found that lymphocytes are radio-sensitive and destroyed by labelling 
with amounts of In-111 required for imaging. I arrived at the Hammersmith in 1979 
to undertake a 3-year Cancer Research Campaign-funded project on labelled lym-
phocytes but with this discovery quickly turned my attention to labelled leucocytes 
and platelets. In those days, Amersham International was not selling In-111-oxine, 
so it had to be prepared in-house (by a radio-chemist, Malcolm Kensett, in the MRC 
Cyclotron Unit). Once a patient had been identifi ed, I would order the In-111-oxine, 
go to the MRC to collect it, take the patient’s blood, go to the Haematology Isotope 
Unit to label it, then take it back to the Radioisotope Unit to inject it and image the 
patient. The Haematology isotope unit under the leadership of Mitchell Lewis, pro-
vided a tertiary service for ferrokinetics, using Fe-59 and Fe-52 (a positron emitter), 
and red cell survival and surface counting studies using Cr-51-labelled red cells. 
The unit also supported studies involving labelled cells, including In-111-labelled 
platelet kinetic studies by Klonikakis et al. [ 9 ], In-113m-labelled red cells and plate-
lets, and studies on the clearance rates of labelled red cells modifi ed by heating or 
antibody coating, undertaken by several workers from the Department of Medicine 
studying reticulo-endothelial (RE) function. 
 The Medical Research Council funded the building of a medical cyclotron on the 
Hammersmith site in 1954 (Fig.  12.2 ). This stimulated much research into 
 Fig. 12.2  The cyclotron being installed in the MRC building at the Hammersmith Hospital in 1956 
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cardiopulmonary physiology and neuro- pathophysiology in collaboration with the 
clinical staff of the Hospital. Pairs of scintillation detectors (front and back) were 
used fi rst (with coincidence counting of positron emission), then planar gamma 
camera imaging, and fi nally positron emission tomography. The fi rst studies were 
carried out in the late 1950s by West and his colleagues [ 10 – 12 ] using the short-
lived positron emitting isotope, oxygen-15 (half life 2.1 min) as C 15 O 2 and 
C 15 O. Lung water distribution was studied with H 2 15 O [ 13 ,  14 ], pulmonary perfu-
sion with infused  13 N 2 in solution [ 15 ], pulmonary haemorrhage with inhaled  11 CO 
[ 16 ], and ventilation with neon-19 [ 17 ]. Rhodes and Hughes [ 18 ] summarized pul-
monary studies using the positron camera. There was also much interest in studies 
of infl ammatory conditions using F-18-fl uorodeoxyglucose ( 18 FDG) [ 19 ,  20 ], and in 
imaging beta-agonist receptors in the heart and lung [ 21 ,  22 ]. 
 Research activity elsewhere in the MRC Cyclotron Unit included the develop-
ment of  18 FDG for imaging the brain (Terry Jones and Richard Frackowiak) and 
myocardium. Camici et al. were one of the fi rst groups to image Rb-82 uptake in the 
myocardium of patients with coronary disease and show increased FDG uptake in 
ischaemic regions [ 23 ]. 
 Many pioneers in nuclear medicine worked at Hammersmith. One of the earliest 
was Charles Galasko who in bone scintigraphy showed in 1968 that 12 of 50 patients 
with apparently ‘early’ breast cancer on clinical, radiological and biochemical 
grounds had positive scintigraphy and developed metastatic disease in the fi rst 5 
years following mastectomy [ 24 ]. Joseph Pfl ug was a pioneer in lymphatic function 
studies and was one of the fi rst to use lymphoscintigraphy. Aga Epenetos, an oncol-
ogist, was one of the fi rst to develop radiolabelled monocloncal antibodies for imag-
ing cancer. Having worked with Keith Britton at St Bartholomew’s and Walter 
Bodmer from the then ICRF, Epenetos continued his work at the Hammersmith. 
Also collaborating with ICRF, Lavender used a very effective monoclonal antibody 
to the platelet fi brinogen receptor for imaging thrombus ([ 25 ]; Fig.  12.3 ).
 Dominic Haskard came to Hammersmith from Guy’s Hospital around 1990 and 
developed very effective monocloncal antibodies to vascular adhesion molecules 
for imaging infl ammation [ 26 ]. Sadly, however, none of these labelled antibodies 
made it into regular nuclear medicine practice. 
 Having developed In-111-oxine cell labelling, workers at the Hammersmith, 
again in collaboration with the MRC Cyclotron Unit (Danpure and Osman), then 
explored other chelating agents and discovered tropolone [ 27 ], which, now that GE 
do not offer In-111-oxine, is the standard agent for In-111 cell labelling. We then 
went on to develop Tc-99m-HMPAO for leucocyte labelling [ 28 ]. Saverymuttu 
demonstrated the extraordinary ability of In-111 and Tc-99m-labelled leucocyte 
scintigraphy to quantify and image infl ammatory bowel disease (Fig.  12.4 ) and pub-
lished numerous papers on its applications in gastroenterology. 
 Other, generally unfunded work, on patient volunteers established the normal 
whole body kinetics and physiological margination sites of granulocytes, and, in 
particular, dismantled the erroneous notion that the vast majority of intravascular 
granulocytes are pooled in the lungs [ 29 ]. It was clearly demonstrated how in sys-
temic infl ammatory diseases, such as pancreatitis, IBD and vasculitis, circulating 
granulocytes become primed, lose deformability and undergo prolonged transit 
through the pulmonary vasculature. This is in contrast to hold-up in the lungs of 
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 Fig. 12.3  Images in a patient who 2 ( top panel ), 3 ( middle panel ) and 4 ( bottom panel ) days 
before receiving a total hip replacement. The In-111-labelled antibody P256 was administered 
shortly after surgery. Note the development of thrombus in the femoral veins and the movement of 
an embolus from the right ventricle to right pulmonary artery (From Ref. [ 25 ]) 
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granulocytes artifi cially activated by the labelling procedure and associated with 
very low intravascular recovery. This work led to quality control guidelines for leu-
cocyte labelling. 
 Another major nuclear medicine landmark in the history of the Hammersmith 
radioisotope unit was the development by Mark Pepys and Philip Hawkins of 
 I-123- labelled serum amyloid protein (SAP) for imaging amyloidosis [ 30 ]. This 
work was dramatically successful and led to the establishment of a separate unit in 
the hospital with its own gamma camera and technical staff, such was the weight of 
referrals from all over the country. So, at one time, there were fi ve separate nuclear 
medicine units on the Hammersmith site! I remember Pepys and Hawkins opening 
champagne in the Radioisotope Unit when they had just witnessed heavy hepatic 
uptake of labelled SAP in a patient with amyloidosis (Fig.  12.5 ). I wondered if the 
celebrations might be premature, having learned that in general when a tracer is not 
functioning properly it is liable to end up in the liver, but this was clearly not the case!
 The spirit of research collaboration at the Hammersmith Hospital fuelled many 















interventional radiology allowed us to inject In-111-labelled platelets directly into 
the splenic artery of patients having arterial catheterization and show conclusively 
that platelets pool in the spleen and are released after a mean residence time of about 
10 min. Plasma exchange for the treatment of immune complex disease was shown 
to be associated with improved RE function as measured by the splenic extraction 
effi ciency of radiolabelled antibody-coated red cells, using simultaneously injected 
In-111-labelled platelets to measure splenic blood fl ow [ 31 ]. Before then, it had 
been thought that RE function could be quantifi ed by the clearance rate of heat-
damaged red cells until we showed that the clearance rate refl ected splenic pooling 
and was therefore, like platelet equilibration between blood and spleen, a measure 
of splenic blood fl ow. Early studies on pulmonary epithelial permeability using 
inhaled Tc-99m-DTPA [ 32 ] and pulmonary endothelial permeability using intrave-
nous In-111-transferrin [ 33 ] were performed by Royston and his co-workers. Davies 
a b
 Fig. 12.5  Hepato-splenic amyloidosis ( a ) compared with normal distribution of I-123-labelled 
SAP ( b ) (From Refs. [ 29 ]) 
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and Walport demonstrated for the fi rst time the whole body kinetics of I-123-
labelled immune complexes [ 34 ]. 
 In the mid-nineties, rotaPET was acquired by what had now been re-named 
the ‘Nuclear Medicine Department’. This was a partial ring detector consisting 
of two separate segments and was used predominantly for FDG imaging of can-
cer but also clinical F-18-DOPA brain imaging. The department was involved in 
early clinical work with In-111-pentetriotide and showed how amino acid infu-
sion blocked renal tubular uptake of the agent [ 35 ]. In research, Harrington and 
Stewart demonstrated the targeting of tumours by In-111-labelled stealth lipo-
somes containing chemotherapeutic agents [ 36 ]. In collaboration with ‘Tiny’ 
Maini from the Institute of Rheumatology, the therapeutic effect of TNFα 
blockade was shown to reduce dramatically leucocyte uptake in rheumatoid 
joints [ 37 ]. Muhammad Mubashar was one of the fi rst workers to image 
P-glycoprotein expression in breast cancer [ 38 ]. As one of the fi rst centres in the 
UK to develop interventional radiology, the Hammersmith Hospital was a refer-
ral centre for conditions such as pulmonary arterio- venous shunts and much 
work with the Department of Respiratory Medicine [ 39 ] was performed to quan-
tify these shunts before and after therapeutic embolization. Finally, elegant 
work performed in collaboration with George Hall, an anaesthetist with an 
interest in exercise physiology, demonstrated in trained athletes undergoing 
maximal brief exercise how platelets and all leucocyte subtypes pool in the 
spleen with similar residence times [ 40 ]. Contrasting the behaviour of red cells 
versus leucocytes and platelets in response to exercise, he showed that the 
spleen is essentially an erectile organ – permanently erect! 
 In the time I was at Hammersmith Hospital (1979–1999), the Hammersmith 
campus was probably the leading medical research hospital in the UK, and enjoyed 
a reputation based on a fantastic multidisciplinary approach and spirit of collabora-
tion, co-operation and clinical support. Clinical research in nuclear medicine that 
goes beyond the evaluation of the latest novel radiopharmaceutical or imaging hard-
ware critically depends on support from the clinicians, and this support was second- 
to- none at the Hammersmith. 
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 Michael  Peters  I did my pre-clinical training at St Mary’s Hospital Medical School where 
I received a BSc in physiology in 1967. I then transferred to Liverpool University and received MB 
ChB in 1970. In 1972, I was appointed as lecturer in physiology in the medical school at Liverpool. 
This is where I discovered my interest in the use of radionuclides to study human physiology and 
did an MD in the use of Xenon-133 to measure hepatic perfusion. Uncertain of what I then wanted 
to do, I went to Australia and became a GP for 4 years, doing many different jobs and discovering 
the attractions of the country. I returned to England in 1978 a few weeks before my mother suc-
cumbed to breast cancer, and after a year in general practice in Liverpool 8 secured a clinical 
research fellowship at the Royal Postgraduate Medical School to work on In-111-labelled lympho-
cytes. There I met my mentor, Peter Lavender, and the great Robert Steiner. There followed 3 years 
of intense research on In-111 cell labelling and then the funding ran out so I joined Glaxo Group 
Research as a Research Physician. My big break came in 1984 when Isky Gordon and Peter 
Lavender created a senior lectureship in radiology split between RPMS and the Institute of Child 
Health. These two great functional radiologists convinced me of the importance of integrated 
imaging, a view later cemented by the introduction of PACS at the Hammersmith Hospital in the 
mid- nineties. In 1988, I became full time at RPMS and then, with Peter’s retirement in 1991, ran 
nuclear medicine at Hammersmith single-handedly until 1999 when I was appointed Foundation 
Professor of Nuclear Medicine in Cambridge. At this time, Cambridge Medical School was grow-
ing rapidly under the leadership of Keith Peters, a man I greatly admired when he was Professor of 
Medicine at RPMS. I spent 6 productive years in Cambridge, working with Edwin Chilvers (respi-
ratory medicine) and Arnie Purushotham (breast cancer), before moving to the new medical school 
in Brighton. The fi rst appointments made in Brighton were Jon Cohen as Dean and Kevin Davies 
as Professor of Medicine, both ex Hammersmith colleagues, so whilst Cambridge was jokingly 
called Hammersmith North, Brighton became known as Hammersmith South. I should have retired 
5 years ago but I am still working full-time and enjoying the research as much as ever. The three 
high points of my career were election to the fellowship of the Academy of Medical Sciences in 
2002, award of a DSc from the University of Liverpool in 2009 and invitation to give the Annual 
Lecture at the spring meeting of the BNMS in Brighton in 2011. 
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